NEUROSCIENCE CLINICAL RESEARCH With millions of patients worldwide affected by neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease, biopharmaceutical companies face significant challenges in drug development, including complex target identification, data variability and the need for sensitive, validated biomarkers. Often, neuroscience-related drug trials demand partnerships with specialty laboratories to stay on track. At MLM Medical Labs, we

GLOBAL ACCESS TO HIGH-QUALITY PBMCs A global network of highly-trained staff to isolate PBMCs per client-specific protocols and SOPs In the rapidly evolving landscape of biopharma drug development, the need for precise, reliable, and scalable cellular resources has never been more critical. At MLM Medical Labs, we specialize in providing high-quality Peripheral Blood Mononuclear Cells

Specialty Testing and Translational Lab Testing At MLM Medical Labs, our scientists excel in collaboratively designing customized solutions to translate your specific research goals into practical therapeutic applications. We provide expert biomarker identification and validation, comprehensive assay development, tech transfer and validation, regulatory guidance, and project management to advance your novel therapeutics through every phase of the

Preclincal Model Development Fibrosis Models Overview Idiopathic pulmonary fibrosis MASH/NASH Systemic Sclerosis New Model Development Further in vivo models Interested in a new model or variation of an existing model? Creating a new preclinical model is a meticulous process that involves innovative scientific approaches. As an established preclinical CRO, we specialize in developing cutting-edge models

Fibrosis Models – IPF Fibrosis Models Overview Idiopathic pulmonary fibrosis MASH/NASH Systemic Sclerosis New Model Development Further in vivo models Bleomycin-induced Idiopathic Pulmonary Fibrosis (IPF) MLM Medical Labs offers an advanced Bleomycin-induced Lung Fibrosis model, established for over a decade in basic research on pulmonary fibrosis. Our methodology employs refined oral aspiration administration, facilitating uniform